

ABOUT US
Explore our extraordinary journey of the pursuit of new frontiers towards functional p53 replacement therapy
Our mission
Empowered by our relentless pursuit of innovation, we are dedicated to advancing oncology treatment by pioneering a novel class of therapeutics. Our mission is to introduce a transformative addition to the clinical arsenal: an off-the-shelf, safe therapy that restores the pinnacle of tumor suppression, the p53 mechanism. Through unwavering commitment to scientific excellence and patient well-being, we aim to redefine the landscape of cancer care, by providing a groundbreaking revolution that can impact the millions of lives affected by cancer


Emerging therapeutic space
In recent years, exosomes have gained attention as a strategy for achieving desirable therapeutic effects without the risks and difficulties of administering intact cells to patients.
Today, a rapidly growing number of companies are developing exosome-based products. AnserBio is at the forefront of future exosome-based therapeutics.

First-in-Class CDV Based Therapy
Our distinctive method entails the direct delivery of healthy non-human p53 protein into tumor cells, offering the potential to improve the treatment outcomes for more than 60% of human cancers, either as a standalone therapy or in combination with other treatments.
Every healthy cell has a built-in DNA repair system, with the p53 protein playing a crucial role as the "guardian of the genome." It helps correct mutations or initiate cell death (apoptosis). However, when the p53 gene is mutated, this protective mechanism is compromised, increasing the risk of cancer or the progression of an existing disease. At AnserBio, we address this issue by delivering functional p53 using nanoparticle-sized cell-derived nanovesicles, called exosomes.

Our DNA
AnserBio is a preclinical stage bio-oncology company, with fully owned IP, an innovative approach, rapid progression from in vitro to preclinical POC in multiple tumor types of high unmet need, with a broad application potential driven by an experienced and passionate team

Our Success towards the pinnacle of Cancer Biotherapy






IP fully owned end-to-end
In early 2023, AnserBio obtained approval for a patent filed in the United States, securing legal ownership of its groundbreaking mechanism. The company now exclusively owns the entire process, from intellectual property (IP) rights to the production of each component, as well as their unique integration and administration procedures.
The confidence of two major investment funds in one year
Based on promising experimental results, two major investment funds, Israel Biotech Fund and Peregrine Ventures, both focused on oncologic therapy, invested in AnserBio during late 2021.
Set to deliver on our milestones


Our new research facilities
Our new facility of nearly 200 square meters of space features a state-of-the-art laboratory, providing a dedicated area to drive innovation
and excellence.
Located close to the prestigious Technion campus, it fosters collaboration and growth within a vibrant tech community. This expansion is made possible through our valued partnership with the exceptional MIVNE team.
